Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?

Impact · against what's priced in

The article provides no new catalysts for BMY or PFE, as the market has already heavily discounted BMY's valuation to 9.4x forward earnings to account for the imminent patent cliffs of Eliquis and Opdivo. The strong current revenue from these drugs is offset by the known future loss of exclusivity, leaving the stock as a value play rather than a growth story.

BMY+0.10

No priced-in read yet